166 related articles for article (PubMed ID: 27986920)
1. Annexin-directed β-glucuronidase for the targeted treatment of solid tumors.
Guillen KP; Ruben EA; Virani N; Harrison RG
Protein Eng Des Sel; 2017 Feb; 30(2):85-94. PubMed ID: 27986920
[TBL] [Abstract][Full Text] [Related]
2. Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.
Krais JJ; De Crescenzo O; Harrison RG
PLoS One; 2013; 8(10):e76403. PubMed ID: 24098491
[TBL] [Abstract][Full Text] [Related]
3. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
4. Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Guillen KP; Restuccia A; Kurkjian C; Harrison RG
Pancreas; 2015 Aug; 44(6):945-52. PubMed ID: 25899647
[TBL] [Abstract][Full Text] [Related]
5. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide.
Krais JJ; Virani N; McKernan PH; Nguyen Q; Fung KM; Sikavitsas VI; Kurkjian C; Harrison RG
Mol Cancer Ther; 2017 Sep; 16(9):1855-1865. PubMed ID: 28522586
[TBL] [Abstract][Full Text] [Related]
7. Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine.
Van Rite BD; Harrison RG
Cancer Lett; 2011 Aug; 307(1):53-61. PubMed ID: 21546157
[TBL] [Abstract][Full Text] [Related]
8. Expression of active human beta-glucuronidase in Sf9 cells infected with recombinant baculovirus.
Sperker B; Mürdter TE; Backman JT; Fritz P; Kroemer HK
Life Sci; 2002 Aug; 71(13):1547-57. PubMed ID: 12127909
[TBL] [Abstract][Full Text] [Related]
9. PET imaging of β-glucuronidase activity by an activity-based 124I-trapping probe for the personalized glucuronide prodrug targeted therapy.
Su YC; Cheng TC; Leu YL; Roffler SR; Wang JY; Chuang CH; Kao CH; Chen KC; Wang HE; Cheng TL
Mol Cancer Ther; 2014 Dec; 13(12):2852-63. PubMed ID: 25277385
[TBL] [Abstract][Full Text] [Related]
10. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature.
Van Rite BD; Lazrak YA; Pagnon ML; Palwai NR; Neves LF; McFetridge PS; Harrison RG
Cancer Lett; 2011 Feb; 301(2):177-84. PubMed ID: 21194833
[TBL] [Abstract][Full Text] [Related]
11. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
12. Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs.
Cheng CM; Chen FM; Lu YL; Tzou SC; Wang JY; Kao CH; Liao KW; Cheng TC; Chuang CH; Chen BM; Roffler S; Cheng TL
Cancer Gene Ther; 2013 May; 20(5):276-81. PubMed ID: 23598434
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeting prodrug-activating bacteria for cancer therapy.
Cheng CM; Lu YL; Chuang KH; Hung WC; Shiea J; Su YC; Kao CH; Chen BM; Roffler S; Cheng TL
Cancer Gene Ther; 2008 Jun; 15(6):393-401. PubMed ID: 18369382
[TBL] [Abstract][Full Text] [Related]
14. Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines.
Chuang KH; Cheng CM; Roffler SR; Lu YL; Lin SR; Wang JY; Tzou WS; Su YC; Chen BM; Cheng TL
Bioconjug Chem; 2006; 17(3):707-14. PubMed ID: 16704208
[TBL] [Abstract][Full Text] [Related]
15. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes.
Chen KC; Cheng TL; Leu YL; Prijovich ZM; Chuang CH; Chen BM; Roffler SR
Cancer Gene Ther; 2007 Feb; 14(2):187-200. PubMed ID: 16977328
[TBL] [Abstract][Full Text] [Related]
16. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy.
Haisma HJ; Sernee MF; Hooijberg E; Brakenhoff RH; vd Meulen-Muileman IH; Pinedo HM; Boven E
Blood; 1998 Jul; 92(1):184-90. PubMed ID: 9639515
[TBL] [Abstract][Full Text] [Related]
17. Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy.
Hsieh YT; Chen KC; Cheng CM; Cheng TL; Tao MH; Roffler SR
PLoS One; 2015; 10(2):e0118028. PubMed ID: 25688562
[TBL] [Abstract][Full Text] [Related]
18. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E
Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732
[TBL] [Abstract][Full Text] [Related]
19. A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.
de Graaf M; Boven E; Oosterhoff D; van der Meulen-Muileman IH; Huls GA; Gerritsen WR; Haisma HJ; Pinedo HM
Br J Cancer; 2002 Mar; 86(5):811-8. PubMed ID: 11875747
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors.
Huang PT; Chen KC; Prijovich ZM; Cheng TL; Leu YL; Roffler SR
Cancer Gene Ther; 2011 Jun; 18(6):381-9. PubMed ID: 21350582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]